Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma.
Nineteen patients resistant to an adriamycin-containing regimen were treated with 4 days of amphotericin B and the same adriamycin-containing chemotherapy regimen that had been given without amphotericin B. Of the 14 evaluable patients (11 with breast carcinoma and three with sarcoma), one patient with breast carcinoma achieved a partial remission and a second patient with breast carcinoma remained stable. All other patients developed progressive disease. Both hematologic and nonhematologic toxicity were significantly increased when amphotericin B was added to chemotherapy.